| Autor: |
Torrence, Paul F, Powell, Linda D |
| Zdroj: |
Antiviral Chemistry & Chemotherapy; December 2002, Vol. 13 Issue: 6 p325-344, 20p |
| Abstrakt: |
Respiratory syncytial virus (RSV) continues as an emerging infectious disease not only among infants and children, but also for the immune-suppressed, hospitalized and the elderly. To date, ribavirin (Virazole) remains the only therapeutic agent approved for the treatment of RSV. The prophylactic administration of palivizumab is problematic and costly. The quest for an efficacious RSV antiviral has produced a greater understanding of the viral fusion process, a new hypothesis for the mechanism of action of ribavirin, and a promising antisense strategy combining the 2′-5′ oligoadenylate antisense (2–5′A-antisense) approach and RSV genomics. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
